Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-347.34 Insider Own1.50% Shs Outstand- Perf Week-22.54%
Market Cap0.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.59M Perf Month-50.00%
Income-12.77M PEG- EPS next Q- Inst Own2.98% Short Float14.07% Perf Quarter-76.94%
Sales0.00M P/S- EPS this Y- Inst Trans61.16% Short Ratio0.32 Perf Half Y-94.68%
Book/sh11.38 P/B0.12 EPS next Y- ROA-382.23% Short Interest0.08M Perf Year-99.59%
Cash/sh6.82 P/C0.20 EPS next 5Y- ROE-903.08% 52W Range1.46 - 349.89 Perf YTD-96.17%
Dividend Est.- P/FCF- EPS past 5Y26.64% ROI-439.42% 52W High-99.62% Beta-1.68
Dividend TTM- Quick Ratio2.64 Sales past 5Y-20.00% Gross Margin- 52W Low-8.22% ATR (14)0.39
Dividend Ex-Date- Current Ratio2.64 EPS Y/Y TTM78.24% Oper. Margin0.00% RSI (14)25.13 Volatility30.72% 19.45%
Employees4 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32760.00
Option/ShortNo / No LT Debt/Eq0.04 EPS Q/Q98.77% Payout- Rel Volume30.63 Prev Close1.56
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsApr 01 BMO Avg Volume259.94K Price1.34
SMA20-24.74% SMA50-57.89% SMA200-95.88% Trades Volume7,961,355 Change-14.10%
Jul-15-24 09:05AM
Jul-11-24 09:20AM
Jul-08-24 09:05AM
Jul-02-24 09:05AM
Jul-01-24 08:45AM
04:05PM Loading…
Jun-28-24 04:05PM
Jun-27-24 09:00AM
Jun-26-24 08:23AM
Jun-24-24 07:16AM
Jun-17-24 08:00AM
Jun-14-24 08:05AM
Jun-12-24 04:15PM
Jun-11-24 09:00AM
08:00AM Loading…
Jun-10-24 08:00AM
May-23-24 10:30AM
May-22-24 09:15AM
May-21-24 08:35AM
May-20-24 08:45AM
May-14-24 09:05AM
May-13-24 10:54AM
Apr-29-24 08:45AM
Apr-25-24 09:15AM
Apr-16-24 08:35AM
Apr-08-24 08:35AM
Apr-01-24 07:35AM
Mar-28-24 09:00AM
Mar-14-24 08:45AM
08:30AM Loading…
Mar-04-24 08:30AM
Feb-02-24 08:55AM
Jan-26-24 08:05AM
Dec-06-23 01:47PM
Dec-05-23 09:05AM
Nov-27-23 08:35AM
Nov-15-23 08:05AM
Oct-31-23 08:45AM
Oct-19-23 08:45AM
Oct-18-23 10:00AM
Oct-17-23 08:35AM
Oct-11-23 09:05AM
Oct-05-23 08:45AM
Sep-29-23 09:00AM
Sep-06-23 09:05AM
Sep-01-23 09:15AM
Aug-29-23 11:06AM
Aug-25-23 09:00AM
Aug-23-23 09:00AM
Aug-16-23 12:00PM
Aug-14-23 08:05AM
Aug-07-23 08:35AM
Aug-03-23 08:30AM
Jul-26-23 11:15AM
Jul-24-23 09:00AM
Jul-05-23 08:45AM
Jun-27-23 08:45AM
Jun-15-23 08:45AM
Jun-13-23 08:35AM
May-22-23 08:45AM
Apr-27-23 09:05AM
Apr-25-23 08:45AM
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.